Navigation Links
Evotec's Registration Statement in Connection With its Proposed Acquisition of Renovis Declared Effective

HAMBURG, Germany and OXFORD, England, March 26 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) announced today that the U.S. Securities and Exchange Commission (SEC) has declared effective Evotec's Registration Statement on Form F-4, which is required for the completion of the merger transaction with Renovis, Inc., a South San Francisco based biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of neurological and inflammatory diseases. This is an important milestone in connection with the proposed acquisition by Evotec of all of the shares of Renovis as it is clearing the way for Renovis to call a stockholders' meeting to vote on the acquisition. Renovis has called a special stockholders' meeting for May 1, 2008 for that purpose.

The board of directors of Renovis and Evotec have approved the transaction and the board of directors of Renovis has recommended that its stockholders approve the transaction.

Forward looking statements

Information set forth in this report contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about the anticipated benefits of Evotec's products, the timing of the completion of the transaction between Evotec and Renovis, the anticipated benefits of the business combination transaction involving Evotec and Renovis, including future financial and operating results, the combined company's plans, objectives, expectations and intentions, the anticipated timing and results of the combined company's clinical and pre-clinical programs, and other statements that are not historical facts. Evotec cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. These include risks and uncertainties relating to: the ability to obtain regulatory approvals of the transaction on the proposed terms and schedule; the parties' ability to complete the transaction because conditions to the closing of the transaction may not be satisfied; the failure to successfully integrate the businesses; unexpected costs or liabilities resulting from the transaction; the risk that synergies from the transaction may not be fully realized or may take longer to realize than expected; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; use and protection of intellectual property; general worldwide economic conditions and related uncertainties; future legislative, regulatory, or tax changes as well as other economic, business and/or competitive factors; and the effect of exchange rate fluctuations on international operations.

The risks included above are not exhaustive. The most recent reports on Form 10-K, Form 10-Q, Form 8-K and other periodic reports filed by Renovis with the Securities and Exchange Commission contain additional factors that could impact the combined company's businesses and financial performance. The parties expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the parties' expectations or any change in events, conditions or circumstances on which any such statement is based.

Additional information

Evotec has filed a Registration Statement on Form F-4 with the Securities and Exchange Commission in connection with the proposed merger. Evotec and Renovis expect to mail a joint proxy statement/prospectus, which will form part of the Registration Statement on Form F-4, to stockholders of Renovis in connection with the proposed merger. This document will contain important information about the merger and should be read before any decision is made with respect to the merger. Investors and stockholders will be able to obtain free copies of this document and any other documents filed or furnished by Evotec or Renovis through the website maintained by the Securities and Exchange Commission at Free copies of these documents may also be obtained from Evotec, by directing a request to Evotec's Investor Relations department at Schnackenburgallee 114, 22525 Hamburg, Germany, or from Renovis, by directing a request to Renovis' Investor Relations department at Two Corporate Drive, South San Francisco, California 94080.

In addition to the documents referenced above, Renovis files or furnishes annual, quarterly and current reports, proxy statements and other information with the Securities and Exchange Commission. You may read and copy any reports, statements or other information filed or furnished by Renovis at the SEC's Public Reference Room at Station Place, 100 F Street, N.E., Washington, D.C. 20549. You can request copies of these documents by writing to the SEC and paying a fee for the copying cost. Please call the SEC at 1-800-SEC-0330 for more information about the operation of the Public Reference Room. Renovis's SEC filings are also available to the public at the SEC's web site at, or at their web site at


Evotec AG

Anne Hennecke

SVP, Investor Relations & Corporate Communications

Phone: +49(0)40-56081-286

Fax: +49(0)40-56081-333


Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kiwa Bio-Tech New Bio-Fertilizer Product Granted Initial Fertilizer Registration Certificate By Ministry of Agriculture of the PRC
2. Marketing and Meeting Details (M2D) Offers Customized Convention Registration and Management Tool to Clients Inside and Outside of Pharma/Biotech
3. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
4. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
5. /CORRECTION//- RxElite Temporarily Suspends Sales Under Its Registration Statement
6. Reliant Pharmaceuticals Announces the Filing of Registration Statement on Form S-1 For an Initial Public Offering
7. National Stem Cell Holding, Inc. Posts Company and Financial Information on the OTCIQ and Has Retained New CFO and Counsel to File Registration Statement With SEC
8. SyntheMed Files Universal Shelf Registration
9. MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock
10. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
11. Anacor Files Registration Statement for Initial Public Offering
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015  Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced today ... independent director, and the Company welcomes Neil Woodford,s ... a recent anonymous internet report on NW Bio.  The ... Linda Powers stated, "We agree with Mr. ...
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased to ... presentations offered in symposia, oral sessions, workshops, awards, and posters. The core ... of applications such as, but not limited to, biotechnology, biomedical, drug discovery, environmental, ...
(Date:11/25/2015)... 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced  today ... rights plan (Rights Plan) in an effort to preserve ... under Section 382 of the Internal Revenue Code (Code). ... use of its NOLs could be substantially limited if ... Section 382 of the Code. In general, an ownership ...
(Date:11/25/2015)... QUEBEC CITY , Nov. 25, 2015 /PRNewswire/ ... "Company"), affirms that its business and prospects remain ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB ... program to completion following review of the final ... met Phase 2 Primary Endpoint in men with ...
Breaking Biology Technology:
(Date:11/9/2015)... 2015 ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition ... Market 2015-2019" report to their offering. ... ) has announced the addition of ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a global ... it has released a new version of its ... North America have already installed ... also includes a FIDO UAF certified server component ... preparing to activate FIDO features. These customers include some ...
Breaking Biology News(10 mins):